OCUMENSION THERAPEUTICS
Ocumension Therapeutics is a China-based ophthalmic pharmaceutical platform company dedicated to identifying, developing, and commercializing first- or best-in-class ophthalmic therapies. The company’s vision is to provide a world-class pharmaceutical total solution to address significant unmet ophthalmic medical needs in China. Since the inception, Ocumension Therapeutics has focused on building a platform integrating specialized capabilities in each major functionality involved in an ophthalmic drug's development cycle, from research and development, manufacturing to commercialization. Ocumension Therapeutics believes its platform positions it well to achieve leadership in China ophthalmology, with a first-mover advantage over future competitors.
OCUMENSION THERAPEUTICS
Social Links:
Industry:
Biotechnology Pharmaceutical Therapeutics
Founded:
2017-01-01
Status:
Active
Contact:
+86 (021)-61493800
Email Addresses:
[email protected]
Total Funding:
200 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible Google Font API Content Delivery Network Euro JsDelivr GStatic Google Static Content Pound Sterling IIS 10 Japanese Yen
Current Employees Featured
Stock Details
Investors List
General Atlantic
General Atlantic investment in Series B - Ocumension Therapeutics
Investments List
| Date | Company | Article | Money raised |
|---|---|---|---|
| 2021-04-14 | Alimera Sciences | Ocumension Therapeutics investment in Post-IPO Equity - Alimera Sciences | 20 M USD |
| 2021-01-03 | EyePoint Pharmaceuticals | Ocumension Therapeutics investment in Post-IPO Equity - EyePoint Pharmaceuticals | 15.7 M USD |
More informations about "Ocumension Therapeutics"
欧康维视,OcuMension
欧康维视治疗成人老视新药ot-802（盐酸毛果芸香碱滴眼液）获cde批准开展iii期临床试验See details»
Ocumension Therapeutics - Crunchbase Investor Profile
Ocumension Therapeutics is a China-based ophthalmic pharmaceutical platform company dedicated to identifying, developing, and commercializing first- or best-in-class ophthalmic …See details»
About Us - Nicox
ITROM is a Dubai based pharmaceutical organization with over 20 years’ experience in the regional ophthalmological scene. ... Ocumension Therapeutics is a China-based …See details»
Ocumension Therapeutics - Drug pipelines, Patents, Clinical trials ...
May 8, 2025 Explore Ocumension Therapeutics with its drug pipeline, therapeutic area, technology platform, 11 clinical trials, 117 news, Disease Domain:Nervous System Diseases, …See details»
Ocumension Therapeutics, 1477:HKG.HZ profile - FT.com
2 days ago Ocumension Therapeutics (1477:HKG.HZ) company profile with history, revenue, mergers & acquisitions, peer analysis, institutional shareholders and more.See details»
Ocumension Therapeutics Receives Approval for OT-703 Real …
May 14, 2025 Chinese ophthalmology specialist Ocumension Therapeutics announced that it has received approval in China to initiate a real-world study in the Bo’ao Lecheng International …See details»
Ocumension Suzhou Biotech Co., Ltd.
了解Ocumension Suzhou Biotech Co., Ltd. (苏州欧康维视生物科技有限公司)公司的药物管线，治疗领域，技术平台，以及它的12项临床试验, 306篇新闻，疾病领域:神经系统疾病，免疫系统疾病，感染，内分泌与代谢疾病，血液及淋巴系 …See details»
Asian Growth Companies With High Insider Ownership In June 2025
Jun 18, 2025 Overview: Ocumension Therapeutics is an ophthalmic pharmaceutical platform company operating in the People's Republic of China, with a market cap of HK$8.22 billion. …See details»
Ocumension Therapeutics ESG Risk Rating - Sustainalytics
Ocumension Therapeutics is an ophthalmic pharmaceutical platform company identifying, developing, and commercializing ophthalmic therapies. It provides a pharmaceutical total …See details»
欧康维视,OcuMension
Ocumension Therapeutics is a China-based ophthalmic pharmaceutical platform company dedicated to identifying, developing and commercializing first- or best-in-class ophthalmic therapies. Our vision is to provide a world-class …See details»
Liu Ye – CEO, OcuMension
Jun 9, 2025 Ye Liu, CEO and cofounder of OcuMension Therapeutics, speaks about the challenges and triumphs of running one of China’s most ambitious ophthalmology-focused …See details»
Ocumension Therapeutics - hkexnews.hk
Ocumension Therapeutics 歐康維視生物 （於開曼群島註冊成立的有限公司） （股份代號：1477） 自願性公告 OT-802 在中國開展III期臨床試驗的臨床試驗授權獲批 本公告乃由歐康維 …See details»
Ocumension Therapeutics - Funding, Financials, Valuation
Ocumension Therapeutics is registered under the ticker HKG:1477 . Ocumension Therapeutics is funded by 3 investors. ... How much funding has this organization raised over time? Show . …See details»
欧康维视,OcuMension
欧康维视治疗青光眼及高眼压症新药OT-301 III期临床试验Denali试验完成全球患者入组See details»
Ocumension Therapeutics (欧康维视生物医药（上海）有限公司)
了解Ocumension Therapeutics (欧康维视生物医药（上海）有限公司)公司的药物管线，治疗领域，技术平台，以及它的11项临床试验, 291篇新闻，疾病领域:神经系统疾病，内分泌与代谢疾 …See details»
欧康维视,OcuMension
欧康维视致力于通过不断地科研创新为中国眼科患者提供优而全的治疗方案。与此同时，我们积极地运用在眼科领域的丰富资源去探索、寻求、开发、生产和获得眼科药物。See details»
欧康维视,OcuMension
Shanghai, China – On August 12, 2024, Ocumension Therapeutics (“OcuMension”) announced an agreement with Alcon Inc. (“Alcon”, and collectively with OcuMension, the “Parties”) where …See details»
Acetazolamide injection - Ocumension Therapeutics - AdisInsight
Acetazolamide injection (also known as OT 302), being developed by Ocumension Therapeutics for the treatment of acute glaucoma (glaucoma in developmental Acetazolamide injection - …See details»
Ocumension Therapeutics - Investments, Portfolio & Company Exits
Ocumension Therapeutics 's most notable exits include EyePoint Pharmaceuticals and Alimera Sciences. Which industries has this organization had the most exits in? Show . EyePoint …See details»
Moxifloxacin/dexamethasone - Ocumension Therapeutics
10 Jul 2020 Ocumension Therapeutics plans a clinical trial for Postoperative inflammation in China You need to be a logged in or subscribed to view this content Request ... If your …See details»